1. Immunotherapy in Lung Cancer: 'The Sky Is the Limit'
Recent years have brought many advancements in the use of immunotherapy to treat non-small cell lung cancer. However, there is still a long way to go, according to Naiyer A. Rizvi, M.D., director of thoracic oncology and the director of immunotherapeutics for the Division of Hematology and Oncology at Columbia University Medical Center. more details...


2. Tagrisso Approved as a First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer
The U.S. Food and Drug Administration recently approved the drug Tagrisso (osimertinib), an oral medication taken once daily, as a first-line treatment for metastatic non-small-cell lung cancer (NSCLC) in patients who have an EGFR mutation.more details...


3. Adjuvant Erlotinib May Benefit Patients With Early-Stage Non-Small Cell Lung Cancer
Adjuvant treatment with erlotinib may benefit patients with early-stage non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR)-mutation. A new study published in the Journal of Clinical Oncologyhas found that EGFR-mutant early-stage NSCLC patients treated with erlotinib experienced improved 2-year disease-free survival (DFS) rates compared with historic genotype-matched controls. more details...


4. FDA approves pembrolizumab for hepatocellular carcinoma, lung cancer indications
The FDA approved pembrolizumab for two additional indications. The agency granted accelerated approval to pembrolizumab (Keytruda, Merck) — an anti-PD-1 therapy — for treatment of patients with hepatocellular carcinoma who previously received sorafenib (Nexavar, Bayer). more details...